CR20200341A - Anticuerpos de unión a gprc5d - Google Patents
Anticuerpos de unión a gprc5dInfo
- Publication number
- CR20200341A CR20200341A CR20200341A CR20200341A CR20200341A CR 20200341 A CR20200341 A CR 20200341A CR 20200341 A CR20200341 A CR 20200341A CR 20200341 A CR20200341 A CR 20200341A CR 20200341 A CR20200341 A CR 20200341A
- Authority
- CR
- Costa Rica
- Prior art keywords
- gprc5d
- antibodies
- antibodies binding
- methods
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 abstract 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
<p>La presente invención se refiere de manera general a anticuerpos que se unen a GPRC5D, incluyendo moléculas de unión a antígeno biespecíficas, p.ej. para activar células T. Además, la presente invención se refiere a polinucleótidos codificantes de dichos anticuerpos y a vectores y células huésped que comprenden dichos polinucleótidos. La invención se refiere además a métodos para producir los anticuerpos y a métodos de utilización de los mismos en el tratamiento de enfermedades.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18156014 | 2018-02-09 | ||
PCT/EP2019/052962 WO2019154890A1 (en) | 2018-02-09 | 2019-02-07 | Antibodies binding to gprc5d |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200341A true CR20200341A (es) | 2020-11-02 |
Family
ID=61189309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200341A CR20200341A (es) | 2018-02-09 | 2019-02-07 | Anticuerpos de unión a gprc5d |
Country Status (20)
Country | Link |
---|---|
US (3) | US20210054094A1 (es) |
EP (1) | EP3749692A1 (es) |
JP (2) | JP2021513334A (es) |
KR (1) | KR20200119833A (es) |
CN (1) | CN111788231A (es) |
AR (1) | AR117392A1 (es) |
AU (1) | AU2019219061A1 (es) |
BR (1) | BR112020015297A2 (es) |
CA (1) | CA3088730A1 (es) |
CL (2) | CL2020001854A1 (es) |
CO (1) | CO2020008940A2 (es) |
CR (1) | CR20200341A (es) |
IL (1) | IL276537A (es) |
MA (1) | MA51734A (es) |
MX (1) | MX2020007012A (es) |
PE (1) | PE20201341A1 (es) |
PH (1) | PH12020551211A1 (es) |
SG (1) | SG11202007578SA (es) |
TW (1) | TWI829667B (es) |
WO (1) | WO2019154890A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
KR20220028035A (ko) * | 2019-07-31 | 2022-03-08 | 에프. 호프만-라 로슈 아게 | Gprc5d에 결합하는 항체 |
EP4168445A1 (en) * | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Immune activating fc domain binding molecules |
CR20230374A (es) | 2021-01-05 | 2023-10-05 | Lanova Medicines Dev Co Ltd | Anticuerpos monoclonales anti-gprc5d y usos de los mismos |
WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
IL305144A (en) | 2021-02-16 | 2023-10-01 | Janssen Pharmaceutica Nv | Trispecific antibodies targeting BCMA, GPRC5D and CD3 |
JP2024510098A (ja) | 2021-02-19 | 2024-03-06 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | 抗GPRC5DxBCMAxCD3三重特異性抗体およびその使用 |
CN116063500A (zh) * | 2021-08-30 | 2023-05-05 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
TW202334222A (zh) * | 2021-11-05 | 2023-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 結合gprc5d的抗體及其用途 |
WO2023115347A1 (zh) * | 2021-12-21 | 2023-06-29 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源抗体 |
WO2023173272A1 (zh) * | 2022-03-15 | 2023-09-21 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源嵌合抗原受体(car)及其应用 |
WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
CN116375867A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 抗gprc5d抗体及其应用 |
WO2023125888A1 (zh) * | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | 一种gprc5d抗体及其应用 |
WO2023143537A1 (zh) * | 2022-01-29 | 2023-08-03 | 恺兴生命科技(上海)有限公司 | Gprc5d抗体及其应用 |
WO2023227062A1 (en) * | 2022-05-27 | 2023-11-30 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
WO2024002308A1 (zh) * | 2022-06-30 | 2024-01-04 | 康诺亚生物医药科技(成都)有限公司 | 一种新型多特异肿瘤抑制剂的开发和应用 |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
CN116003598A (zh) * | 2022-08-30 | 2023-04-25 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
WO2024050797A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京天广实生物技术股份有限公司 | 结合bcma、gprc5d和cd3的多特异性抗体及其用途 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
NZ603037A (en) | 2003-01-22 | 2014-05-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
DK1871805T3 (da) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
KR101839163B1 (ko) | 2010-06-08 | 2018-03-15 | 제넨테크, 인크. | 시스테인 조작된 항체 및 접합체 |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
RS57744B1 (sr) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
JP6152120B2 (ja) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc受容体に基づくアフィニティークロマトグラフィー |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
EA201891502A1 (ru) * | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
CA2931113C (en) | 2013-12-20 | 2023-07-11 | Genentech, Inc. | Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
WO2016016299A1 (en) | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
EP3204416A1 (en) * | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
EP3209684B1 (en) | 2014-10-24 | 2020-12-23 | F.Hoffmann-La Roche Ag | Vh-vl-interdomain angle based antibody humanization |
KR102602417B1 (ko) * | 2014-12-05 | 2023-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
ES2905315T3 (es) * | 2015-04-13 | 2022-04-07 | Pfizer | Anticuerpos terapéuticos y sus usos |
CN107787332B (zh) | 2015-04-24 | 2022-09-09 | 豪夫迈·罗氏有限公司 | 多特异性抗原结合蛋白 |
TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
WO2018117786A1 (es) | 2016-12-19 | 2018-06-28 | Campo Y Ramos Juan Carlos | Método de moldeo científico autoajustado por aprendizaje recurrente en tiempo real |
-
2019
- 2019-02-01 TW TW108104312A patent/TWI829667B/zh active
- 2019-02-07 CR CR20200341A patent/CR20200341A/es unknown
- 2019-02-07 MX MX2020007012A patent/MX2020007012A/es unknown
- 2019-02-07 SG SG11202007578SA patent/SG11202007578SA/en unknown
- 2019-02-07 CA CA3088730A patent/CA3088730A1/en active Pending
- 2019-02-07 KR KR1020207025330A patent/KR20200119833A/ko unknown
- 2019-02-07 BR BR112020015297-8A patent/BR112020015297A2/pt unknown
- 2019-02-07 WO PCT/EP2019/052962 patent/WO2019154890A1/en unknown
- 2019-02-07 MA MA051734A patent/MA51734A/fr unknown
- 2019-02-07 AU AU2019219061A patent/AU2019219061A1/en active Pending
- 2019-02-07 EP EP19703331.9A patent/EP3749692A1/en active Pending
- 2019-02-07 PE PE2020000977A patent/PE20201341A1/es unknown
- 2019-02-07 JP JP2020542386A patent/JP2021513334A/ja active Pending
- 2019-02-07 CN CN201980016091.9A patent/CN111788231A/zh active Pending
- 2019-02-08 AR ARP190100315A patent/AR117392A1/es unknown
-
2020
- 2020-07-13 CL CL2020001854A patent/CL2020001854A1/es unknown
- 2020-07-21 CO CONC2020/0008940A patent/CO2020008940A2/es unknown
- 2020-07-31 US US16/944,292 patent/US20210054094A1/en not_active Abandoned
- 2020-08-05 IL IL276537A patent/IL276537A/en unknown
- 2020-08-07 PH PH12020551211A patent/PH12020551211A1/en unknown
-
2022
- 2022-09-23 US US17/935,017 patent/US20230212308A1/en not_active Abandoned
-
2023
- 2023-03-29 CL CL2023000907A patent/CL2023000907A1/es unknown
- 2023-04-28 US US18/309,037 patent/US20240067749A1/en not_active Abandoned
- 2023-07-31 JP JP2023124161A patent/JP2023159115A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA51734A (fr) | 2021-05-19 |
CL2023000907A1 (es) | 2023-11-17 |
MX2020007012A (es) | 2020-09-07 |
AU2019219061A1 (en) | 2020-08-06 |
CN111788231A (zh) | 2020-10-16 |
AR117392A1 (es) | 2021-08-04 |
PE20201341A1 (es) | 2020-11-25 |
TWI829667B (zh) | 2024-01-21 |
WO2019154890A1 (en) | 2019-08-15 |
IL276537A (en) | 2020-09-30 |
PH12020551211A1 (en) | 2021-05-17 |
US20240067749A1 (en) | 2024-02-29 |
TW201936641A (zh) | 2019-09-16 |
EP3749692A1 (en) | 2020-12-16 |
CL2020001854A1 (es) | 2020-10-23 |
US20210054094A1 (en) | 2021-02-25 |
JP2023159115A (ja) | 2023-10-31 |
US20230212308A1 (en) | 2023-07-06 |
BR112020015297A2 (pt) | 2020-12-08 |
CA3088730A1 (en) | 2019-08-15 |
CO2020008940A2 (es) | 2020-08-31 |
JP2021513334A (ja) | 2021-05-27 |
RU2020129004A (ru) | 2022-03-09 |
KR20200119833A (ko) | 2020-10-20 |
SG11202007578SA (en) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200341A (es) | Anticuerpos de unión a gprc5d | |
MY194642A (en) | Antibodies binding to cd3 | |
MX2022001156A (es) | Anticuerpos que se fijan a gprc5d. | |
MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
PH12018500634A1 (en) | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules | |
MX2017006571A (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t. | |
MX2022001831A (es) | Anticuerpos terapeuticos y sus usos. | |
EA201890390A1 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
PH12016502505A1 (en) | Bispecific t cell activating antigen binding molecules | |
MX2020013122A (es) | Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). | |
PH12019502274A1 (en) | Antibodies binding to steap-1 | |
MX2014001916A (es) | Moleculas biespecificas de union a antigeno. | |
PH12020550952A1 (en) | Antibodies binding to hla-a2/wt1 | |
CR20220256A (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
PH12020551153A1 (en) | Antibodies specific for cd70 and their uses | |
MX2022003110A (es) | Anticuerpos biespecificos contra ceacam5 y cd3. | |
MX2022015197A (es) | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
MX2022015203A (es) | Moleculas de union al dominio fc de activacion inmunitaria. | |
MX2022016069A (es) | Anticuerpos que se unen a cd3 y cd19. | |
CR20220639A (es) | Anticuerpos que se unen a cd3 y folr1 | |
CR20220628A (es) | Anticuerpos que se unen a cd3 |